Liraglutide Alleviates Hepatic Steatosis and Liver Injury in T2MD Rats via a GLP-1R Dependent AMPK Pathway

Liraglutide Alleviates Hepatic Steatosis and Liver Injury in T2MD Rats via a GLP-1R Dependent AMPK Pathway

Non-alcoholic fatty liver disease (NAFLD), ranging from non-alcoholic fatty liver to non-alcoholic steatohepatitis, can be prevalent in patients with type 2 diabetes mellitus (T2DM). However, no antidiabetic drug has been approved for the treatment of NAFLD in T2DM patients. Multiple daily injection...

Full description

Bibliographic Details
Main Authors: Rui Zhou, Chuman Lin, Yanzhen Cheng, Xiaoyun Zhuo, Qinghua Li, Wen Xu, Liang Zhao, Li Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Pharmacology
Subjects:
liraglutide
hepatic steatosis
liver injury
T2DM
PPARα
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2020.600175/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2020.600175/full

Similar Items